Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Fineline Cube Sep 14, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...

Policy / Regulatory

CDE Launches CARE Plan to Streamline Rare Disease Drug Development

Fineline Cube Sep 14, 2024

The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...

Company

Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment

Fineline Cube Sep 13, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...

Company Deals

Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery

Fineline Cube Sep 13, 2024

Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an...

Company Drug

Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis

Fineline Cube Sep 13, 2024

Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...

Company Drug

Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment

Fineline Cube Sep 13, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...

Company Policy / Regulatory

South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan

Fineline Cube Sep 13, 2024

South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to...

Company Deals Digital

Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion

Fineline Cube Sep 13, 2024

Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...

Company Deals

Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China

Fineline Cube Sep 13, 2024

Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals,...

Company Deals

ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs

Fineline Cube Sep 13, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined...

Company Deals

Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies

Fineline Cube Sep 13, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Deals

Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations

Fineline Cube Sep 13, 2024

MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round,...

General/Other

Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director

Fineline Cube Sep 13, 2024

The Ministry of Human Resources and Social Security has announced key leadership changes within the...

Company Deals

Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology

Fineline Cube Sep 13, 2024

Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market,...

Company Medical Device

Yestar Healthcare’s 2024 Interim Report Reflects Impact of Volume-Based Procurement on Revenue

Fineline Cube Sep 13, 2024

Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic...

Company Drug

Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives

Fineline Cube Sep 12, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...

Company Policy / Regulatory

FDA Uncovers Data Management Failures in Medical Device Labs, Assessing Regulatory Impact

Fineline Cube Sep 12, 2024

Medical device manufacturers relying on laboratory services for testing and validation data have come under...

Company Legal / IP R&D

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

Fineline Cube Sep 12, 2024

Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Posts pagination

1 … 350 351 352 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.